Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Triple negative breast cancer can be divided into additional subtypes. Here, using omics analyses, the authors show that in the mesenchymal subtype expression of MHC-1 is repressed and that this can be restored by using drugs that target subunits of the epigenetic modifier PRC2.

Guardado en:

Detalles Bibliográficos
Autores principales:	Brian D. Lehmann, Antonio Colaprico, Tiago C. Silva, Jianjiao Chen, Hanbing An, Yuguang Ban, Hanchen Huang, Lily Wang, Jamaal L. James, Justin M. Balko, Paula I. Gonzalez-Ericsson, Melinda E. Sanders, Bing Zhang, Jennifer A. Pietenpol, X. Steven Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/0cee2f33898a4f86bcaa6cb1a2d39df1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0cee2f33898a4f86bcaa6cb1a2d39df1
record_format	dspace
spelling	oai:doaj.org-article:0cee2f33898a4f86bcaa6cb1a2d39df12021-11-08T11:11:45ZMulti-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes10.1038/s41467-021-26502-62041-1723https://doaj.org/article/0cee2f33898a4f86bcaa6cb1a2d39df12021-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-26502-6https://doaj.org/toc/2041-1723Triple negative breast cancer can be divided into additional subtypes. Here, using omics analyses, the authors show that in the mesenchymal subtype expression of MHC-1 is repressed and that this can be restored by using drugs that target subunits of the epigenetic modifier PRC2.Brian D. LehmannAntonio ColapricoTiago C. SilvaJianjiao ChenHanbing AnYuguang BanHanchen HuangLily WangJamaal L. JamesJustin M. BalkoPaula I. Gonzalez-EricssonMelinda E. SandersBing ZhangJennifer A. PietenpolX. Steven ChenNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Brian D. Lehmann Antonio Colaprico Tiago C. Silva Jianjiao Chen Hanbing An Yuguang Ban Hanchen Huang Lily Wang Jamaal L. James Justin M. Balko Paula I. Gonzalez-Ericsson Melinda E. Sanders Bing Zhang Jennifer A. Pietenpol X. Steven Chen Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
description	Triple negative breast cancer can be divided into additional subtypes. Here, using omics analyses, the authors show that in the mesenchymal subtype expression of MHC-1 is repressed and that this can be restored by using drugs that target subunits of the epigenetic modifier PRC2.
format	article
author	Brian D. Lehmann Antonio Colaprico Tiago C. Silva Jianjiao Chen Hanbing An Yuguang Ban Hanchen Huang Lily Wang Jamaal L. James Justin M. Balko Paula I. Gonzalez-Ericsson Melinda E. Sanders Bing Zhang Jennifer A. Pietenpol X. Steven Chen
author_facet	Brian D. Lehmann Antonio Colaprico Tiago C. Silva Jianjiao Chen Hanbing An Yuguang Ban Hanchen Huang Lily Wang Jamaal L. James Justin M. Balko Paula I. Gonzalez-Ericsson Melinda E. Sanders Bing Zhang Jennifer A. Pietenpol X. Steven Chen
author_sort	Brian D. Lehmann
title	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
title_short	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
title_full	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
title_fullStr	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
title_full_unstemmed	Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
title_sort	multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0cee2f33898a4f86bcaa6cb1a2d39df1
work_keys_str_mv	AT briandlehmann multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT antoniocolaprico multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT tiagocsilva multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT jianjiaochen multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT hanbingan multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT yuguangban multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT hanchenhuang multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT lilywang multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT jamaalljames multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT justinmbalko multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT paulaigonzalezericsson multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT melindaesanders multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT bingzhang multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT jenniferapietenpol multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes AT xstevenchen multiomicsanalysisidentifiestherapeuticvulnerabilitiesintriplenegativebreastcancersubtypes
_version_	1718442305215528960

Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes

Ejemplares similares